Literature DB >> 18484428

Effect of oxybutynin on exercise-induced sweating in healthy individuals.

Marthe van Houte1, Ankie M Harmsze, Vera H M Deneer, Ron A Tupker.   

Abstract

OBJECTIVES: Oxybutynin has been proven to be effective in patients with generalized hyperhidrosis. Some dermatoses aggravate as a result of sweating. Therefore, oxybutynin might also be useful in such normohidrotic patients. The aim was to evaluate the efficacy and safety of different doses of oxybutynin on exercise-induced sweating in healthy individuals.
METHODS: Two randomized, double-blind, placebo-controlled, cross-over studies were performed, in which two different dosages (2.5 and 5 mg) of oxybutynin were tested. The degree of sweating was determined by transepidermal water loss (TEWL) measurement on the forearm and the hand during exercise. Furthermore, the effectiveness was evaluated by means of the individual's global assessment score, and side effects were noted.
RESULTS: No significant differences between oxybutynin and placebo were found on the forearm and the hand at both dosages of oxybutynin with respect to TEWL values and the individual's global assessment score. Side effects consisted of diarrhoea, dizziness, dry mouth and dry eyes.
CONCLUSIONS: In this model, oxybutynin did not result in inhibition of exercise-induced sweating in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18484428     DOI: 10.1080/09546630701418754

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  2 in total

Review 1.  Oxybutynin as an alternative treatment for hyperhidrosis.

Authors:  Sergio Delort; Evaldo Marchi; Marcos Antônio Corrêa
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

2.  Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.

Authors:  Altair da Silva Costa; Luiz Eduardo Villaça Leão; José Ernesto Succi; Joao Aléssio Juliano Perfeito; Adauto Filho Castelo; Erika Rymkiewicz; Marco Filho Aurelio Marchetti
Journal:  Clinics (Sao Paulo)       Date:  2014-02       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.